Sadahisa Ogasawara

Chiba, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 174 publications

Phase Ib/II trial to evaluate the safety and efficacy of atezolizumab and bevacizumab as adjuvant therapy following carbon-ion radiotherapy in hepatocellular carcinoma (VANGUARD): study protocol.

Phase Ib/II trial to evaluate the safety and efficacy of atezolizumab and bevacizumab as adjuvant therapy following carbon-ion radiotherapy in hepatocellular carcinoma (VANGUARD): study protocol.

Journal: BMJ open
Published: June 02, 2026

On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial.

On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial.

Journal: The lancet. Gastroenterology & hepatology
Published: May 07, 2026

Clinical Outcomes After Failed Endoscopic Detorsion for Sigmoid Volvulus: A Single-Center Retrospective Cohort Study.

Clinical Outcomes After Failed Endoscopic Detorsion for Sigmoid Volvulus: A Single-Center Retrospective Cohort Study.

Journal: DEN open
Published: April 27, 2026

Discordance Between Japanese and European Definitions of Acute-on-Chronic Liver Failure in Alcohol-Related Cirrhosis: Insights From a 10-Year Consecutive Cohort.

Discordance Between Japanese and European Definitions of Acute-on-Chronic Liver Failure in Alcohol-Related Cirrhosis: Insights From a 10-Year Consecutive Cohort.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: February 21, 2026

Real-World Evidence from a Nationwide Prospective Study of the Efficacy/Safety of Systemic Therapy for Unresectable Hepatocellular Carcinoma: First 1,000 Patients of the PRISM Study.

Real-World Evidence from a Nationwide Prospective Study of the Efficacy/Safety of Systemic Therapy for Unresectable Hepatocellular Carcinoma: First 1,000 Patients of the PRISM Study.

Journal: Liver cancer
Published: December 03, 2025

Durable Disease Control With Atezolizumab Plus Bevacizumab but Limited Post-Progression Outcomes: A Multicenter Real-World Study in Advanced Hepatocellular Carcinoma.

Durable Disease Control With Atezolizumab Plus Bevacizumab but Limited Post-Progression Outcomes: A Multicenter Real-World Study in Advanced Hepatocellular Carcinoma.

Journal: Cancer medicine
Published: November 30, 2025

Privacy preserving digital platform for patient reported outcomes in inflammatory bowel disease.

Privacy preserving digital platform for patient reported outcomes in inflammatory bowel disease.

Journal: NPJ digital medicine
Published: November 20, 2025

Intratumoral Heamorrhage Induced by Atezolizumab plus Bevacizumab Combination Therapy in Patients with Hepatocellular Carcinoma.

Intratumoral Heamorrhage Induced by Atezolizumab plus Bevacizumab Combination Therapy in Patients with Hepatocellular Carcinoma.

Journal: Oncology
Published: November 15, 2025

Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinoma.

Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinoma.

Journal: Annals of hepatology
Published: October 03, 2025

A Multicenter Phase II Study on Atezolizumab plus Bevacizumab Combination Therapy in Patients with Unresectable Hepatocellular Carcinoma and Child-Pugh Classification B Cirrhosis: CHALLENGE Trial.

A Multicenter Phase II Study on Atezolizumab plus Bevacizumab Combination Therapy in Patients with Unresectable Hepatocellular Carcinoma and Child-Pugh Classification B Cirrhosis: CHALLENGE Trial.

Journal: Liver cancer
Published: September 27, 2025

Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naïve Advanced Hepatocellular Carcinoma: Long-Term Follow-up of the Open-Label, Phase II KEYNOTE-224 Study.

Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naïve Advanced Hepatocellular Carcinoma: Long-Term Follow-up of the Open-Label, Phase II KEYNOTE-224 Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 24, 2025

Temporal trends and regional variations in hepatocellular carcinoma etiology: a multinational study across Asia.

Temporal trends and regional variations in hepatocellular carcinoma etiology: a multinational study across Asia.

Journal: Hepatology international
Published: September 06, 2025
Showing 1-12 of 174

Last Updated: 09/26/2026